• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.

作者信息

Chatenoud L, Legendre C, Ferran C, Bach J F, Kreis H

机构信息

INSERM U25, Hopital Necker, Paris, France.

出版信息

Transplantation. 1991 Feb;51(2):334-8. doi: 10.1097/00007890-199102000-00012.

DOI:10.1097/00007890-199102000-00012
PMID:1899732
Abstract

The data presented extend to a larger series of 27 consecutive renal allograft recipients treated prophylactically with OKT3 our previous observation that the acute OKT3-induced clinical syndrome is related to massive release in the circulation of some cytokines, among which are tumor necrosis factor and interferon gamma. In addition, a pilot randomized study was set up including 12 consecutive patients receiving high-dose corticosteroid treatment (0.5 g solumedrol) either before or at the same time as the first OKT3 injection. Results confirm that when corticosteroids are given in sufficient amount and, importantly, 1 hr before the first OKT3 injection, they significantly decrease the release of both tumor necrosis factor and interferon gamma. In addition, the pretreatment with corticosteroids may totally abolish the IL-2 release induced by OKT3. Given the key role the massive although transient cytokine release plays in determining the OKT3-induced acute syndrome, these results provide the biological basis supporting a precise kinetics of administration of high-dose corticosteroids to better decrease the severity of the clinical reaction.

摘要

相似文献

1
Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.
Transplantation. 1991 Feb;51(2):334-8. doi: 10.1097/00007890-199102000-00012.
2
In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.注射OKT3后体内细胞的激活。全身细胞因子的释放及皮质类固醇的调节作用。
Transplantation. 1990 Apr;49(4):697-702. doi: 10.1097/00007890-199004000-00009.
3
A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.接受OKT3诱导治疗的肾移植受者中重组人白细胞介素-10的一项试点试验。
Transplantation. 1997 Oct 15;64(7):999-1006. doi: 10.1097/00007890-199710150-00012.
4
Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.
Transplantation. 1992 Dec;54(6):997-1002. doi: 10.1097/00007890-199212000-00011.
5
CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.CD3抗体诱导肾移植受者产生白细胞介素-10:体内和体外分析
Transplantation. 1999 Sep 15;68(5):616-22. doi: 10.1097/00007890-199909150-00004.
6
In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients. Differential regulation of TNF-sR55 and TNF-sR75.
Transplantation. 1995 May 27;59(10):1470-5. doi: 10.1097/00007890-199505270-00019.
7
Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.肾移植受者注射OKT3单克隆抗体后血清中肿瘤坏死因子、白细胞介素-2和γ-干扰素的释放
Transplantation. 1989 Apr;47(4):606-8. doi: 10.1097/00007890-198904000-00008.
8
OKT3 first-dose reaction: association with T cell subsets and cytokine release.OKT3首剂反应:与T细胞亚群及细胞因子释放的关联
Kidney Int. 1991 Jan;39(1):141-8. doi: 10.1038/ki.1991.18.
9
[T lymphocyte activation induced in vivo by the first injection of OKT3 monoclonal antibodies].[首次注射OKT3单克隆抗体在体内诱导的T淋巴细胞活化]
C R Acad Sci III. 1988;307(19):833-6.
10
Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.用T10B9.1A31或OKT3治疗肾移植排斥反应:一项II期临床试验的最终分析
Transplantation. 1997 Jul 27;64(2):274-81. doi: 10.1097/00007890-199707270-00017.

引用本文的文献

1
Harnessing Newton's third-law paradigm to treat autoimmune diseases and chronic inflammations.利用牛顿第三定律范式治疗自身免疫性疾病和慢性炎症。
Inflamm Res. 2020 Sep;69(9):813-824. doi: 10.1007/s00011-020-01374-6. Epub 2020 Jun 26.
2
Non-antigenic and antigenic interventions in type 1 diabetes.1型糖尿病的非抗原性和抗原性干预措施。
Hum Vaccin Immunother. 2014;10(4):838-46. doi: 10.4161/hv.26890. Epub 2013 Oct 28.
3
Teplizumab therapy for type 1 diabetes.特立帕肽治疗 1 型糖尿病。
Expert Opin Biol Ther. 2010 Mar;10(3):459-65. doi: 10.1517/14712591003598843.
4
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.新的免疫抑制方法:口服CD3特异性抗体治疗自身免疫性疾病。
J Neurol Sci. 2008 Nov 15;274(1-2):9-12. doi: 10.1016/j.jns.2008.07.027. Epub 2008 Sep 18.
5
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.EpCAM/CD3特异性双特异性T细胞衔接器(BiTE)抗体在小鼠中的治疗窗口由人类所缺乏的表达EpCAM的淋巴细胞亚群决定。
Cancer Immunol Immunother. 2009 Jan;58(1):95-109. doi: 10.1007/s00262-008-0529-y. Epub 2008 Jul 2.
6
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.莫罗单抗-CD3:对其药理学及作为实体器官移植排斥反应预防药物应用的重新评估。
Drugs. 1996 May;51(5):865-94. doi: 10.2165/00003495-199651050-00010.
7
Prevention and management of the adverse effects associated with immunosuppressive therapy.免疫抑制治疗相关不良反应的预防与管理。
Drug Saf. 1993 Aug;9(2):104-31. doi: 10.2165/00002018-199309020-00004.
8
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.IgA和IgG2a抗CD3同种型转换变体的体内效应。
J Clin Invest. 1994 Jun;93(6):2519-25. doi: 10.1172/JCI117262.
9
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.抗肿瘤坏死因子在体内调节抗CD3触发的T细胞细胞因子基因表达。
J Clin Invest. 1994 May;93(5):2189-96. doi: 10.1172/JCI117215.
10
Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment.CD3/TCR单克隆抗体治疗后细胞因子释放及白细胞群体动态变化
J Clin Immunol. 1992 May;12(3):170-7. doi: 10.1007/BF00918085.